Ivarmacitinib sulfateProduct ingredient for Ivarmacitinib

Name
Ivarmacitinib sulfate
Drug Entry
Ivarmacitinib

Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,11,14,16 ankylosing spondylitis,7 rheumatoid arthritis,8 psoriatic arthritis,9 graft-versus-host disease,2,10 vitiligo,12 ulcerative colitis,13 alopecia areata,15 and primary membranous nephropathy.17

Accession Number
DBSALT003216
Structure
Synonyms
SHR-0302 sulfate / SHR0302 sulfate
UNII
CN7B3Z5G04
CAS Number
1639419-51-4
Weight
Average: 512.56
Monoisotopic: 512.126022873
Chemical Formula
C18H24N8O6S2
InChI Key
XVVWQCLRGHYWPI-OOWXMNGOSA-N
InChI
InChI=1S/C18H22N8O2S.H2O4S/c1-25(15-13-3-4-19-14(13)20-9-21-15)12-5-10-7-26(8-11(10)6-12)18(27)23-17-22-16(28-2)24-29-17;1-5(2,3)4/h3-4,9-12H,5-8H2,1-2H3,(H,19,20,21)(H,22,23,24,27);(H2,1,2,3,4)/t10-,11+,12+;
IUPAC Name
(3aR,5S,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]-octahydrocyclopenta[c]pyrrole-2-carboxamide; sulfuric acid
SMILES
OS(O)(=O)=O.[H][C@@]12C[C@H](C[C@]1([H])CN(C2)C(=O)NC1=NC(OC)=NS1)N(C)C1=NC=NC2=C1C=CN2
ChemSpider
88298508
Predicted Properties
PropertyValueSource
Water Solubility0.0228 mg/mLALOGPS
logP1.96ALOGPS
logP1.82Chemaxon
logS-4.3ALOGPS
pKa (Strongest Acidic)6.91Chemaxon
pKa (Strongest Basic)6.27Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area112.16 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity111.49 m3·mol-1Chemaxon
Polarizability42.47 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon